The Pharmaceutical Industry in Today's Economic Recession 2009

As these words are being written down, the world isaway and put their assets in sectors with none to
going through extraordinary times, with a financiallow risks. However, exit routes also play an important
crisis not experienced since the world wars. Marketsrole. Unless there is a fast return, there is only one
are in turmoils and uncertainty is part of manyway for a biotech/pharma company to be profitable:
businesses and industries. Several financial analysis arethrough acquisition by a larger biotech or
available for us to read, but the content oftenpharmaceutical company. Because of the way biotech
difficult to digest. The recession has badly affectedand pharmaceutical companies usually grow, this is
many industries who are now desperately seekinghighly likely to happen. In this scenario, smaller
help, such as the car industry. But what will be thecompanies, unable to sustain their finance could
specific impacts of the economic recession on thepotentially ask bigger biotech/pharma company to
biotech and pharmaceutical industry.bankroll them, allowing the industry to survive and
The pharmaceutical and health-care industry haveeven grow.
historically been relatively immune to economicAs a matter of fact, that second hypothesis has
turndowns, because illness doesn't take a vacation.already started to take place. With today's economic
Yet, with the ongoing recession, financial support willturndowns, big drug companies are on a shopping
be reduced. Therefore, like in other industries, it isspree. With the stock market prices tumbling,
expected that the most affected by the reducedacquisitions are becoming cheaper. Also, struggling to
availability in funding will be the early stage biotechfind loans and capital, smaller companies are now
and pharmaceutical companies who need funding. Butmore enticed to turn to the bigger ones to survive.
is there more to come?Many big pharma companies, such as Bristol-Myers,
There are a few possible speculations.GlaxoSmithKline or Wyeth, have been staring down
1.There is a possibility that things will get worst duebillions worth of drug-patent expirations and many of
to the fact that the market will be so uncertain thatthem have few up-and-coming drugs to fill the blank.
no financial investors will be willing to back up anyThis economic crisis has given them exceptional
company with a risky profile, notably in regards toopportunities to find bargains amongst the
the early or short term investments. In the event ofunfortunate small to medium companies in need for
this scenario, all industries will be affected. Companiesfunding.
with little cash will go one by one, until the economyNonetheless, it is important to remember that
heals.although the recession has yield great merges and
2.Investors are often reluctant to put their moneyacquisitions by the bigger biotech/pharma companies,
into biotech and pharmaceutical companies becausethe biotech and pharmaceutical industry is also very
of other very attractive industries such as buyoutsaffected by the economic slowdown, and many of
and investments in resources (mines, oil). As thethem are cutting jobs and closing factories. The belief
economic crisis goes on, the opportunities for capitalof pharmaceutical and the health-care industry
will decline further. Because of the known and wellimmunity to economic turndown is now on hold, and
recorded risk profile of the biotech andso is the hope for new medicine breakthrough.
pharmaceutical industry, investors are going to stay